LONDON, Jan. 17, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces ...

Autolus Therapeutics (AUTL) announces an oral presentation and three poster presentations accepted to the 2025 Tandem Meetings ...

Avanza Fonder AB bought a new position in shares of Autolus Therapeutics plc (NASDAQ:AUTL – Free Report) during the fourth quarter, according to its most recent filing with the SEC.The fund ...

In a report released today, Gil Blum from Needham maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report), with a price target ...

Autolus Therapeutics received acceptance for an oral presentation and three poster presentations at the prestigious 2025 Tandem Meetings, highlighting their commitment to disseminating research ...

LONDON, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed ...

JPMorgan Chase & Co.’s holdings in Autolus Therapeutics were worth $4,663,000 at the end of the most recent quarter. Other large investors have also recently bought and sold shares of the company.

(MENAFN- GlobeNewsWire - Nasdaq) LONDON, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company ...

Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies to patients, today announces ...